Sangamo Therapeutics Company
Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Headquarters:
Richmond, California, United States
Total Funding:
522100000.0
Founded Date:
1995-01-01
Acquisitions Number:
2
Employee Number:
251-500
Last Funding Type:
Post-IPO Equity
Investors Number:
3.0
Last Funding Date:
2019-04-03
Technology:
Biotechnology, Genetics, Pharmaceutical, Therapeutics
Funding Status:
IPO
Estimated Revenue:
$10M to $50M
Industry:
End-to-End Drug Development